Therapeutic Monoclonal Antibodies, 2006-2011 Maximising the Growth Potential of a Stocked Pipeline

While the pharmaceutical as a whole is suffering from single digit growth, thin uninspiring pipelines and pressure from an ever-aggressive generics industry – not so for monoclonal antibody therapies. The market for monoclonal antibody treatments is one of the most exciting segments of the pharmaceutical industry today. Are you and your organisation benefiting from this growth?

The monoclonal market is set to expand dramatically. Ten years ago there were only two monoclonal antibody drugs on the world market, now there are nineteen FDA approved therapies – including six blockbuster drugs. The market in 2005 was worth over $13bn, worldwide, representing an astounding growth of 37% - can you believe it? Well you should and to make sure you capture an increased share of this growth order this report NOW. Biotech pipelines are overflowing with over 160 monoclonal antibody based drugs; the market is thriving!

Will the current monoclonal blockbusters continue to grow? What are the hottest projects in the pipeline? What will restrain the market in the future? These are questions you need to know the answers to.

Buy visiongain’s new report to find out!

Included in this report:

This exhaustive and informative report includes over 100 pages of in-depth, up-to-date, analysis and over 70 tables and figures, detailing the current market and possible future developments. The following important issues are covered in detail:

Visiongain’s forecast for the world monoclonal antibody market, 2006-2011

Drivers and restraints of the fast growing world monoclonal antibody market are identified and discussed

An analysis of strengths, weaknesses opportunities and threats (SWOT) for the monoclonal antibody market

Summaries and revenue forecasts for the leading monoclonal antibody drugs, 2006-2011

A thorough examination of the monoclonal antibody pipeline

An assessment of future developments, including new antibody formats and conjugated antibodies

You cannot afford to ignore this expanding market. A small investment today will be the catalyst of a great return for your company tomorrow.

Unique benefits to you when you order this report

- Immediate access through our exclusive Reading Room

- You can access your report whichever country you are in without using harddrive space

- Primary research throughout. You will not find this information anywhere else

- Report stored in your reading room for ever

- Copies can be printed off for offline reading

- Packed with charts, analysis, figures, graphs and tables

Organizations listed:

Abbott Labs

Ablnyx

Advanced Molecular Evolution

Affimed

Alexion

Alfacell

Amgen

Antisoma

Aphton

AstraZeneca

Bayer

Biogen Idec

Biomira

Bristol-Myers Squibb

Cambridge Antibody Technology

Cancer Research UK

Cell Genesys

Celltrion

Celtic Pharma

Centocor

Dainippon Sumitomo

Dompe

Duke University

Eli Lilly

Estere

Genentech

GenMab

Gilead Sciences

GlaxoSmithKline

IDM Pharma

Igeneon

Immunogen

Johnson and Johnson

Medarex

MedImmune

Medison Pharma

Merck KGaA

Micromet

National Cancer Institute (US)

National Institutes of Health (US)

Orphan Pharma International

PDL BioPharma

Peregrine

Pfizer

Procter & Gamble

Roche

Schering AG

Schering-Plough

Seattle Genetics

Serono

Sloane Kettering Institute

Stanford University

Tanabe

Targa Therapeutics

UCB

United Therapeutics

VaxGen

ViRexx

Viventia Biotech

Wilex

Wyeth

Lead Analyst: Dr Tom Newton Publication Date: 07/12/06 Pages: 117

Single user licence: The Report is delivered via an on-line reading room. One use access only, the report is in Flash format in a printable format.

Department: Report is delivered via an on line reading room. Five user access only, the report is in Flash format in a printable format.

Company/site wide licence: The report is delivered in email format as a PDF document with no locking system attached. The report can be loaded onto the company's intranet site.

Table of Contents

Price
Single User Licence $3998.00
Department Licence 5 Users $7998.00
Company-wide Intranet Licence $17,998.00